ALX Oncology
NEWS
With recent high-profile failures, experts say safety concerns and a lack of diversification are hindering the field—but still hold out hope for an approval.
The clinical-stage company joins several others in the anti-CD47 space which have dropped studies amid poor results, including Gilead Sciences’ decision late last month to stop a Phase III trial.
Lightstone Ventures recently announced the closing of Lightstone Ventures III, securing $375 million to invest in early-stage firms that develop high-impact technologies that can change lives.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
Due to the registration potential of the mid-stage studies, the U.S. Food and Drug Administration requested the company complete a standard safety study, which amounts to a partial clinical hold on the study.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
ALX Oncology will partner with pharma giant Merck to evaluate a combination of its CD47 inhibitor with Keytruda as a potential treatment for patients with Head & Neck Squamous Cell Carcinoma.
IN THE PRESS